There are currently 6 active clinical trials seeking participants for Renal Insufficiency research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and New York.
Product Surveillance Registry
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
All
Ages:
All
Trial Updated:
03/25/2024
Locations: Not set, Birmingham, Alabama +362 locations
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Recruiting
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/25/2024
Locations: Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida +3 locations
Conditions: Renal Insufficiency
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: AKDHC Marana Surgery Center, Marana, Arizona +6 locations
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
A Study of LY3502970 in Participants With Normal and Impaired Renal Function
Recruiting
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
02/27/2024
Locations: Clinical Pharmacology of Miami, Miami, Florida +3 locations
Conditions: Renal Insufficiency, Healthy
Spironolactone in CKD Enabled by Chlorthalidone: PILOT
Recruiting
Highly prevalent among patients with chronic kidney disease (CKD) and poorly controlled blood pressure (BP), is a modifiable risk factor to abrogate both kidney failure progression and cardiovascular (CV) disease. Spironolactone (SPL), a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, however one of the most common side effects is an increase of serum potassium (K). This side effect occurs frequently in those who suffer from CKD. Alternatively, chlorthalido... Read More
Gender:
All
Ages:
Between 19 years and 110 years
Trial Updated:
08/11/2023
Locations: Richard L Roudebush VA Medical Center, Indianapolis, Indiana
Conditions: Renal Insufficiency, Chronic Hypertension
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
Recruiting
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
Gender:
All
Ages:
Between 18 years and 82 years
Trial Updated:
02/17/2023
Locations: Orlando Clinical Research Center, Orlando, Florida +1 locations
Conditions: Renal Insufficiency, Kidney Diseases